Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer

Hiroshi Saeki, Shuhei Ito, Motonori Futatsugi, Yasue Kimura, Takefumi Ohga, Keizo Sugimachi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme involved in the degradation of 5-FU. DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy. The DPD activity showed interpatient variability (mean: 325.5 pmol/min/mg protein). 5-FU-related side-effects tended to be registered more frequently in patients with low DPD activity. In particular, nausea occurred in 30.8 % of patients in the high DPD activity group but, in 70.6 % in those with low DPD activity (p < 0.05). The relationship between the histological response to therapy and DPD activity was nil. We propose that determination of DPD activity prior to initiation of 5-FU-based chemotherapy for patients with esophageal cancer could aid in identifying those at risk for toxicity.

Original languageEnglish
Pages (from-to)3789-3792
Number of pages4
JournalAnticancer research
Volume22
Issue number6 B
Publication statusPublished - Nov 1 2002

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
Esophageal Neoplasms
Fluorouracil
Cytostatic Agents
Nausea
Blood Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Saeki, H., Ito, S., Futatsugi, M., Kimura, Y., Ohga, T., & Sugimachi, K. (2002). Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. Anticancer research, 22(6 B), 3789-3792.

Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. / Saeki, Hiroshi; Ito, Shuhei; Futatsugi, Motonori; Kimura, Yasue; Ohga, Takefumi; Sugimachi, Keizo.

In: Anticancer research, Vol. 22, No. 6 B, 01.11.2002, p. 3789-3792.

Research output: Contribution to journalArticle

Saeki, H, Ito, S, Futatsugi, M, Kimura, Y, Ohga, T & Sugimachi, K 2002, 'Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer', Anticancer research, vol. 22, no. 6 B, pp. 3789-3792.
Saeki H, Ito S, Futatsugi M, Kimura Y, Ohga T, Sugimachi K. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. Anticancer research. 2002 Nov 1;22(6 B):3789-3792.
Saeki, Hiroshi ; Ito, Shuhei ; Futatsugi, Motonori ; Kimura, Yasue ; Ohga, Takefumi ; Sugimachi, Keizo. / Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. In: Anticancer research. 2002 ; Vol. 22, No. 6 B. pp. 3789-3792.
@article{9344ec34653a4ea3aa3c51211c409ac3,
title = "Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer",
abstract = "Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme involved in the degradation of 5-FU. DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy. The DPD activity showed interpatient variability (mean: 325.5 pmol/min/mg protein). 5-FU-related side-effects tended to be registered more frequently in patients with low DPD activity. In particular, nausea occurred in 30.8 {\%} of patients in the high DPD activity group but, in 70.6 {\%} in those with low DPD activity (p < 0.05). The relationship between the histological response to therapy and DPD activity was nil. We propose that determination of DPD activity prior to initiation of 5-FU-based chemotherapy for patients with esophageal cancer could aid in identifying those at risk for toxicity.",
author = "Hiroshi Saeki and Shuhei Ito and Motonori Futatsugi and Yasue Kimura and Takefumi Ohga and Keizo Sugimachi",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "22",
pages = "3789--3792",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer

AU - Saeki, Hiroshi

AU - Ito, Shuhei

AU - Futatsugi, Motonori

AU - Kimura, Yasue

AU - Ohga, Takefumi

AU - Sugimachi, Keizo

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme involved in the degradation of 5-FU. DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy. The DPD activity showed interpatient variability (mean: 325.5 pmol/min/mg protein). 5-FU-related side-effects tended to be registered more frequently in patients with low DPD activity. In particular, nausea occurred in 30.8 % of patients in the high DPD activity group but, in 70.6 % in those with low DPD activity (p < 0.05). The relationship between the histological response to therapy and DPD activity was nil. We propose that determination of DPD activity prior to initiation of 5-FU-based chemotherapy for patients with esophageal cancer could aid in identifying those at risk for toxicity.

AB - Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme involved in the degradation of 5-FU. DPD activity in peripheral blood mononuclear cells of 30 esophageal cancer patients treated with 5-FU and low-dose CDDP with irradiation was determined at the beginning of each cytostatic cycle, the objective being to determine if DPD activity is related to the occurrence of side-effects and responses to therapy. The DPD activity showed interpatient variability (mean: 325.5 pmol/min/mg protein). 5-FU-related side-effects tended to be registered more frequently in patients with low DPD activity. In particular, nausea occurred in 30.8 % of patients in the high DPD activity group but, in 70.6 % in those with low DPD activity (p < 0.05). The relationship between the histological response to therapy and DPD activity was nil. We propose that determination of DPD activity prior to initiation of 5-FU-based chemotherapy for patients with esophageal cancer could aid in identifying those at risk for toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0036875153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036875153&partnerID=8YFLogxK

M3 - Article

C2 - 12552994

AN - SCOPUS:0036875153

VL - 22

SP - 3789

EP - 3792

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -